PAPER Ludolph AC, Brettschneider J, Weishaupt JH

Amyotrophic lateral sclerosis.

Curr Opin Neurol. 2012 Oct;25(5):530-5. PubMed.

PAPER Calvo A, Moglia C, Canosa A, Cistaro A, Valentini C, Carrara G, Soldano E, Ilardi A, Bersano E, Bertuzzo D, Brunetti M, Ossola I, Restagno G, Chiò A

Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive-compulsive disorder associated to GGGGCC expansion of the c9orf72 gene.

J Neurol. 2012 Dec;259(12):2723-5. Epub 2012 Aug 24 PubMed.

PAPER Mehta SG, Khare M, Ramani R, Watts GD, Simon M, Osann KE, Donkervoort S, Dec E, Nalbandian A, Platt J, Pasquali M, Wang A, Mozaffar T, Smith CD, Kimonis VE

Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia.

Clin Genet. 2013 May;83(5):422-31. Epub 2012 Oct 4 PubMed.

PAPER Jin SC, Pastor P, Cooper B, Cervantes S, Benitez BA, Razquin C, Goate A, Ibero-American Alzheimer Disease Genetics Group Researchers, Cruchaga C

Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort.

Alzheimers Res Ther. 2012 Aug 20;4(4):34. PubMed.

PAPER Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH

The genetics and neuropathology of amyotrophic lateral sclerosis.

Acta Neuropathol. 2012 Sep;124(3):339-52. Epub 2012 Aug 2 PubMed.

PAPER Borroni B, Grassi M, Premi E, Gazzina S, Alberici A, Cosseddu M, Paghera B, Padovani A

Neuroanatomical correlates of behavioural phenotypes in behavioural variant of frontotemporal dementia.

Behav Brain Res. 2012 Dec 1;235(2):124-9. Epub 2012 Aug 10 PubMed.

PAPER Spina S, Van Laar AD, Murrell JR, Hamilton RL, Kofler JK, Epperson F, Farlow MR, Lopez OL, Quinlan J, DeKosky ST, Ghetti B

Phenotypic variability in three families with valosin-containing protein mutation.

Eur J Neurol. 2013 Feb;20(2):251-8. Epub 2012 Aug 20 PubMed.

PAPER Kanemaru K, Kameda N, Yamanouchi H

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.

Neurology. 2000 May 9;54(9):1875-6. PubMed.

PAPER Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Arch Neurol. 2001 Mar;58(3):373-9. PubMed.

PAPER Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

Neurology. 1999 May 12;52(8):1555-62. PubMed.

PAPER Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Mariën P, De Deyn PP

Neuropsychological and behavioural correlates of CSF biomarkers in dementia.

Neurochem Int. 2006 Mar;48(4):286-95. Epub 2006 Jan 24 PubMed.

Acetyl-l-carnitine HCI

THERAPEUTICS Sigma-Tau Pharmaceuticals ALCAR Supplement, Dietary Other ALCAR has been found to be cardioprotective as well as neuroprotective in a number of disease models (hypoxia/ischmia, traumatic brain injury) (Zanelli et al., 2005). Beneficial effects of ALCAR on

AF 102B

THERAPEUTICS SnowBrand Pharmaceuticals, Inc. cevimeline HCL Evoxac™ Small Molecule Cholinergic System Hypo-activity of the cholinergic system is associated AD and cognitive decline. Two different strategies have been used to increase cholinergic acitvity  in the AD br

Siew-Lan Ang

University of Aberdeen, Current Alz Advisor
London, United Kingdom

Stephanie Paulovich

Boston, United States